Research programme: muscarinic M2 receptor antagonists - InnovivaAlternative Names: Overactive bladder therapeutics - Innoviva; THRX-326151
Latest Information Update: 23 Nov 2016
At a glance
- Originator Theravance
- Developer Innoviva
- Class Piperidines; Pyrrolidines; Small molecules
- Mechanism of Action Muscarinic M2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 10 Sep 2007 Preclinical trials in Overactive bladder in USA (IV)